Nucleic acid simultaneously inhibiting expression of mTOR gene and STAT3 gene
AssigneeCurigin Co., Ltd.
InventorJin-Woo Choi
Life of this patent
Estimating the term…
Loading patent…
AssigneeCurigin Co., Ltd.
InventorJin-Woo Choi
Estimating the term…
The present invention relates to a nucleic acid molecule simultaneously inhibiting the expression of mTOR gene and STAT3 gene, and an anticancer pharmaceutical composition comprising the same. More specifically, base-paired siRNA or shRNA of the present invention, designed to simultaneously inhibit the expression of cancer-related mTOR gene and STAT3 gene in order to surmount the problem that siRNA or shRNA does not achieve high therapeutic effects due to the target specificity thereof, has the effect of promoting the death of cancer cells. In addition, the nucleic acid has the effect of synergistically enhancing the apoptosis of cancer cells when used in combination with an anticancer agent, finding useful applications as an anticancer composition or anticancer aid against various carcinomas.
A siRNA or shRNA simultaneously inhibiting the expression of mammalian target of rapamycin (mTOR) gene and signal transducer and activator of transcription 3 (STAT3) gene,
A nucleic acid molecule encoding a shRNA which simultaneously inhibits the expression of mammalian target of rapamycin (mTOR) gene and signal transducer and activator of transcription 3 (STAT3) gene, the nucleotide sequence comprises the sequence of SEQ ID NO:
Dependencies are inferred from the claim text.